Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Incyte Corporation

3 Buy-Rated Biotechs to Buy in May

Despite logistical hurdles, the biotech industry is expected to expand solidly in the coming years on lucrative federal investments and strong demand. Therefore, we think it could be wise to bet on the stocks of quality biotech companies Biogen (BIIB), BioNTech (BNTX), and Incyte (INCY). These stocks are rated ‘Buy’…

Mizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang Lifted

Mizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang Lifted

The US Patent Trial and Appeal Board (PTAB) issued a final written decision in favor of Concert Pharmaceuticals Inc (NASDAQ:CNCE) regarding the post-grant review (PGR) for the '659 method-of-use patent. The '659 patent claims methods of treating hair loss, including alopecia areata with certain doses of CTP-543, a deuterated form of ruxolitinib, JAK 1/2…

Despite Q1 Earnings Miss, Incyte Shares Jump On Revised FY22 Sales Guidance

Despite Q1 Earnings Miss, Incyte Shares Jump On Revised FY22 Sales Guidance

Incyte Corporation's (NASDAQ:INCY) Q1 adjusted EPS reached $0.55, compared to $0.67 posted a year ago. Analysts had estimated $0.68. Sales increased 21% Y/Y to $733.24 million, missing the consensus of $750.66 million. The company's operating expenses increased 22% to $616.69 million, with the cost of sales up 45.8%, R&D costs up 15%,…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Incyte's Ruxolitinib Shows Further Improvement In Facial, Total Body Re-pigmentation At 52 Weeks In Skin Disorder

Incyte Corporation (NASDAQ: INCY)

FDA Extends Decision Date For Incyte's Ruxolitinib In Vitiligo Skin Disorder

The FDA has extended the review period for Incyte Corporation's (NASDAQ:INCY) supplemental application for ruxolitinib cream (Opzelura) for vitiligo. The Prescription Drug User Fee Act (PDUFA) action date has been extended by three months to July 18 from April 18. The FDA extended the PDUFA action date to review additional data from the ongoing Phase 3…

Eli Lilly's JAK Inhibitor Baricitinib Cuts Death Risk By 13% In COVID-19 Patients

According to a British study, Eli Lilly And Co (NYSE:LLY) and Incyte Corporation's (NASDAQ:INCY) Olumiant (baricitinib) reduced the risk of death in hospitalized COVID-19 patients by 13%. According to a Reuters report, more than 8,000 patients were administered baricitinib in addition to standard of care in the RECOVERY Trial. Results showed that 546 patients…

CTI BioPharma's Bone Marrow Cancer Drug Scores FDA Approval

The FDA approved CTI BioPharma Corp's (NASDAQ:CTIC) Vonjo (pacritinib) for treating adult patients with myelofibrosis, a type of bone marrow cancer with low blood platelets count. Pacritinib is a JAK inhibitor and will compete with Incyte Corporation's (NASDAQ:INCY) Jakafi and Bristol Myers Squibb's Co (NYSE:BMY) Inrebic, which were approved in 2011 and 2019, respectively for myelofibrosis. CTI…

inkl

Read news from The Economist, FT, and more,
with one subscription

Why Are Incyte Shares Trading Lower Today?

Why Are Incyte Shares Trading Lower Today?

Incyte Corporation's (NASDAQ: INCY)

Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With Merus

Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With Merus

Incyte Corporation (NASDAQ: INCY) is

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Eli Lilly And Co

Bristol Myers Squibb

Incyte Corporation

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

373,912 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play